NADMED successful in 3.5 million euro Series A round

NADMED secures 3.5 million euros to roll out its NAD measurement methods worldwide. The aim is to improve personalized medicine through more precise diagnoses and therapies.

Hellsinki, August 22, 2024 - Finnish biotech company NADMED has secured €3.5 million in a Series A funding round to bring its NAD (nicotinamide adenine dinucleotide) measurement technology to the international market, particularly the US. This technology makes it possible to measure NAD levels precisely and quickly, which could support personalized treatment of various diseases. The round was led by Nordic Science Investments (NSI), with additional support from Voima Ventures and the University of Helsinki Fund.

Importance of NAD and glutathione for medicine

NAD and glutathione are crucial molecules for energy production, cell repair and growth in the body. An imbalance of these molecules is associated with numerous age-related diseases such as metabolic disorders, cancer, heart and brain diseases and muscle wasting. NADMED has developed a method to accurately and efficiently measure all four forms of NAD in fresh blood samples. This technology is based on research conducted by Professor Anu Suomalainen Wartiovaara at the University of Helsinki.

Expansion of global presence and new group of investors

NADMED plans to use the new funds to expand its presence in the USA and further develop its technology. The company is aiming for greater dissemination of its measurement methods, which are used in particular in personalized medicine and therapy monitoring. NSI sees great potential in the technology and supports NADMED with a strong network to drive expansion.

Support from leading scientists and customer base

With customers in 27 countries, including hospitals, universities and pharmaceutical companies, and the scientific support of Professor Wartiovaara, NADMED offers a breakthrough solution for the precise measurement of NAD and glutathione. This innovation could play a key role in personalized medicine and the advancement of metabolic research in the coming years.